TY - JOUR T1 - Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. JO - Eur Heart J PY - 1998/04/01 AU - van Hout BA AU - Bowman L AU - Zelinger DJ AU - Simoons ML ED - VL - 19 Suppl D SP - D59 EP - D66 Y2 - 2025/05/06 ER -